Purpose A multicenter randomized phase II trial to evaluate two treatment strategies in the
first-line management of advanced non–small-cell lung cancer (NSCLC) patients with a …

Purpose: Erlotinib has proven activity in pretreated patients with advanced non–small cell
lung cancer (NSCLC). We evaluated erlotinib in the frontline treatment of advanced NSCLC …

Background We conducted a randomized, placebo-controlled, double-blind trial to
determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival …

Purpose Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer …

Introduction The aim of this study was to evaluate the efficacy and safety of Erlotinib in
Japanese patients with previously treated non-small cell lung cancer (NSCLC). Available …

7022 Background: In phase II studies, erlotinib has shown single agent activity in a number
of tumor types, including NSCLC. NCIC CTG BR. 21 is a randomized, placebo-controlled …

Introduction: This phase 2 study was conducted to determine the efficacy and safety of
erlotinib alone and with bortezomib in patients with non-small cell lung cancer (NSCLC) …

7010 Background: Oral erlotinib is a potent HER1/EGFR tyrosine kinase-phosphorylation
inhibitor with single-agent antitumor activity and has shown additive effects when added to …

Background Erlotinib, docetaxel, and pemetrexed are approved for the second-line
treatment of non-small-cell lung cancer (NSCLC), but no head-to-head data from large …

Background Many patients with advanced non-small-cell lung cancer (NSCLC) receive only
active supportive care because of poor performance status or presence of several …